Ret Proto-Oncogene anticorps (AA 702-848)
-
- Antigène Voir toutes Ret Proto-Oncogene (RET) Anticorps
- Ret Proto-Oncogene (RET)
-
Épitope
- AA 702-848
-
Reactivité
- Humain
-
Hôte
- Souris
-
Clonalité
- Monoclonal
-
Conjugué
- Cet anticorp Ret Proto-Oncogene est non-conjugé
-
Application
- ELISA, Coating (Coat)
- Purification
- Purified by Protein A/G
- Immunogène
- Recombinant fragment (around aa 702-848) of human RET protein (exact sequence is proprietary)
- Clone
- RET-2663
- Isotype
- IgG2b kappa
- Top Product
- Discover our top product RET Anticorps primaire
-
-
- Indications d'application
-
Positive Control: Breast, Prostate or Colon Carcinoma.
Known Application: ELISA (For coating, order Ab without BSA)Optimal dilution for a specific application should be determined.
- Restrictions
- For Research Use only
-
- Concentration
- 200 μg/mL
- Buffer
- 10 mM PBS with 0.05 % BSA & 0.05 % azide.
- Agent conservateur
- Sodium azide
- Précaution d'utilisation
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- Stock
- 4 °C,-80 °C
- Stockage commentaire
- Antibody with azide - store at 2 to 8°C. Antibody without azide - store at -20 to -80°C. Antibody is stable for 24 months. Non-hazardous. No MSDS required.
- Date de péremption
- 24 months
-
- Antigène
- Ret Proto-Oncogene (RET)
- Autre désignation
- RET (RET Produits)
- Synonymes
- anticorps c-ret, anticorps cret, anticorps etID315074.13, anticorps ret1, anticorps wu:fd13h01, anticorps X-ret, anticorps ret-A, anticorps xret, anticorps RET, anticorps MTC1, anticorps CDHF12, anticorps CDHR16, anticorps HSCR1, anticorps MEN2A, anticorps MEN2B, anticorps PTC, anticorps RET-ELE1, anticorps RET51, anticorps RET9, anticorps c-Ret, anticorps ret proto-oncogene receptor tyrosine kinase, anticorps ret proto-oncogene S homeolog, anticorps ret proto-oncogene, anticorps ret, anticorps ret.S, anticorps RET, anticorps Ret
- Sujet
- The Ret proto-oncogene is structurally related to the growing family of tyrosine kinase transmembrane receptors and is involved in GDNF signaling. RET expression is reported in several regions of the central nervous system, in the developing cranial nerve ganglia and a subset of cells within dorsal root ganglia, in motor neurons in the spinal cord and hindbrain, in neuro-retina and the growing tips of the renal collecting ducts in developing kidney.Alterations in RETgene are associated with diseases including papillary thyroid carcinoma, multiple endocrine neoplasia (type 2A and 2B), familial medullary thyroid carcinoma, and a congenital developmental disorder known as Hirschsprung's disease.
- Poids moléculaire
- 150kDa (precursor), 170kDa (Mature)
- ID gène
- 5979
- UniProt
- P07949
- Pathways
- Signalisation RTK, Dopaminergic Neurogenesis, Regulation of Cell Size, Tube Formation
-